Ortataxel is under clinical development by Spectrum Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ortataxel’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ortataxel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ortataxel overview

Ortataxel (BAY 59-8862, IDN-5109) is under development for the treatment of taxane-refractory solid tumors. It is a new chemical entity (NCE). The drug candidate is administered through intravenous and oral routes. It is a semi-synthetic taxane acts by targeting tubulin protein. It was also under development for the treatment of advanced renal cell carcinoma, recurrent glioblastoma, metastatic breast cancer, non-small cell lung carcinoma (NSCLC) and non-Hodgkin's lymphoma.

Spectrum Pharmaceuticals overview

Spectrum Pharmaceuticals (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. This product is in phase 3 trails.; Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.

Quick View Ortataxel LOA Data

Report Segments
  • Innovator
Drug Name
  • Ortataxel
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.